摘要
目的探讨噻托溴铵对COPD稳定期患者炎症因子和肺功能的影响。方法方便选取2016年3月—2017年3月到某院进行慢性肺阻塞稳定期疾病治疗的患者120例,随机分为两组,每组60例,对照组患者使用常规治疗方法,实验组患者在常规治疗的基础上,使用噻托溴铵,对两组患者治疗有效率进行分析。结果对患者血清hs-CRP,TNF-水平进行分析比较,治疗后实验组hs-CRP与空腹胰岛素分别为(1.16±0.25)、(1.55±0.22),均显著低于对照组患者(1.57±0.35)、(2.03±0.39),差异有统计学意义(t=5.493、4.382,P<0.05)。治疗后实验组的FVC、FEV1、FVC/FEV1分别为(1.79±0.31)、(1.22±0.23)、(0.79±0.19),均显著高于对照组患者(1.58±0.32)、(0.97±0.13)及(0.62±0.18),均差异有统计学意义(t=3.274、4.382、2.495,P<0.05)。实验组患者经过治疗后,治疗总有效率为93.33%,对照组患者治疗有效率仅为76.67%,数据对比差异有统计学意义(χ2=4.396,P=0.029)。结论对稳定期慢性肺阻塞疾总病患者的治疗,可以推荐使用噻托溴铵进行治疗,治疗效果较为有效,对患者身体健康有积极作用。
Objective To study the effect of tiotropium bromide on the inflammatory factors and lung function of patients with stable COPD. Methods 120 cases of patients with stable COPD in our hospital from March 2016 to March 2017 were convenient selected and randomly divided into two groups with 60 cases in each, the control group used the routine therapy,while the experimental group were treated with tiotropium bromide on the basis of the control group, and the treatment effective rate of the two groups was analyzed. Results The hs-CRP and fasting insulin in the experimental group after treatment were obviously lower than those in the control group[（1.16±0.25）,（1.55±0.22） vs（1.57±0.35）,（2.03±0.39）], and the differences were statistically significant（t=5.493,4.382,P〈0.05）, after treatment, the FVC,FEV1,FVC/FEV1 in the experimental group after treatment were obviously higher than those in the control group [（1.79±0.31）,（1.22±0.23）,（0.79±0.19） vs（1.58±0.32）,（0.97±0.13）,（0.62±0.18）], and the differences were statistically significant（t =3.274,4.382,2.495,P〈0.05）, and the treatment effective rate in the experimental group after treatment and in the control group was respectively 93.33% and76.67%, and the difference was obvious, with statistical significance（χ2=4.396,P =0.029）. Conclusion The effect of tiotropium bromide in treatment of patients with stable COPD is obvious, which has a positive effect on the physical health of patients.
作者
任师磊
王蕾
朱付莲
REN Shi-lei;WANG Lei;ZHU Fu-lian(Department of Respiration Medicine,Heze Munieiple Hospital,Heze,Shandong Province,274000 China;Department of Acceptance,Heze Munieiple Hospital,Heze,Shandong Province,274000 China)
出处
《中外医疗》
2018年第11期10-12,22,共4页
China & Foreign Medical Treatment
